<DOC>
	<DOCNO>NCT01171963</DOCNO>
	<brief_summary>The purpose study ass efficacy , immunogenicity safety GSK Biologicals ' liquid human rotavirus vaccine healthy Chinese infant 6 16 week age .</brief_summary>
	<brief_title>Study Assess Efficacy , Immunogenicity Safety Liquid Human Rotavirus Vaccine , Healthy Chinese Infants</brief_title>
	<detailed_description>Subjects receive routine childhood vaccination accord expand program immunisation recommendation China . There two treatment group ( liquid human rotavirus vaccine placebo ) . The study also two immunogenicity subgroup comprise subject treatment group . The immunogenicity subgroup 1 ass immunogenicity liquid human rotavirus vaccine immunogenicity subgroup 2 assess immunogenicity liquid human rotavirus vaccine also immunogenicity oral poliovirus vaccine diphtheria tetanus acellular pertussis vaccine give concomitantly liquid human rotavirus vaccine placebo . This protocol post update follow Protocol Amendment 2 , date 05 August 2011 . The impacted section protocol posting : Outcome Measures Section .</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/Legally Acceptable Representatives comply requirement protocol . A male female infant Chinese origin , include , 6 16 week age time first vaccination . Written inform consent obtain parents/Legally Acceptable Representatives subject . Healthy subject establish medical history clinical examination enter study . Born gestation period 36 42 week inclusive . Child care . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Planned administration/administration vaccine foreseen study protocol within 14 day dose study vaccine ( ) end 14 day first dose human rotavirus vaccine placebo except routine childhood vaccination . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Any clinically significant history gastrointestinal disease include uncorrected congenital malformation ( Meckel 's diverticulum ) gastrointestinal tract would predispose intussusception . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine . Major congenital defect serious chronic illness . History confirm rotavirus gastroenteritis . Acute disease and/or fever time enrolment . Gastroenteritis within 7 day precede study vaccine placebo administration . Administration immunoglobulins and/or blood product since birth plan administration study period . In addition criterion mention , follow criterion applicable subject immunogenicity subgroup 2 : History diphtheria , tetanus pertussis disease . History seizures progressive neurological disease . Previous vaccination diphtheria , tetanus , pertussis poliomyelitis .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Liquid human retrovirus vaccine</keyword>
</DOC>